Aroa Biosurgery Geçmiş Kazanç Performansı

Geçmiş kriter kontrolleri 0/6

Aroa Biosurgery has been growing earnings at an average annual rate of 11.5%, while the Biotechs industry saw earnings growing at 12.6% annually. Revenues have been growing at an average rate of 29.2% per year.

Anahtar bilgiler

11.5%

Kazanç büyüme oranı

79.4%

EPS büyüme oranı

Biotechs Sektör Büyümesi9.6%
Gelir büyüme oranı29.2%
Özkaynak getirisi-11.2%
Net Marj-15.4%
Son Kazanç Güncellemesi31 Mar 2024

Yakın geçmiş performans güncellemeleri

Recent updates

Take Care Before Jumping Onto Aroa Biosurgery Limited (ASX:ARX) Even Though It's 29% Cheaper

Aug 22
Take Care Before Jumping Onto Aroa Biosurgery Limited (ASX:ARX) Even Though It's 29% Cheaper

Investors Aren't Entirely Convinced By Aroa Biosurgery Limited's (ASX:ARX) Revenues

Jun 12
Investors Aren't Entirely Convinced By Aroa Biosurgery Limited's (ASX:ARX) Revenues

Here's Why We're Not At All Concerned With Aroa Biosurgery's (ASX:ARX) Cash Burn Situation

Mar 25
Here's Why We're Not At All Concerned With Aroa Biosurgery's (ASX:ARX) Cash Burn Situation

Why Investors Shouldn't Be Surprised By Aroa Biosurgery Limited's (ASX:ARX) 25% Share Price Plunge

Jan 30
Why Investors Shouldn't Be Surprised By Aroa Biosurgery Limited's (ASX:ARX) 25% Share Price Plunge

Aroa Biosurgery Limited's (ASX:ARX) Revenues Are Not Doing Enough For Some Investors

Nov 14
Aroa Biosurgery Limited's (ASX:ARX) Revenues Are Not Doing Enough For Some Investors

Industry Analysts Just Made A Captivating Upgrade To Their Aroa Biosurgery Limited (ASX:ARX) Revenue Forecasts

Nov 02
Industry Analysts Just Made A Captivating Upgrade To Their Aroa Biosurgery Limited (ASX:ARX) Revenue Forecasts

Aroa Biosurgery Limited's (ASX:ARX) Intrinsic Value Is Potentially 50% Above Its Share Price

Oct 25
Aroa Biosurgery Limited's (ASX:ARX) Intrinsic Value Is Potentially 50% Above Its Share Price

We Think Aroa Biosurgery (ASX:ARX) Can Easily Afford To Drive Business Growth

May 13
We Think Aroa Biosurgery (ASX:ARX) Can Easily Afford To Drive Business Growth

Here's What Analysts Are Forecasting For Aroa Biosurgery Limited (ASX:ARX) After Its Annual Results

May 26
Here's What Analysts Are Forecasting For Aroa Biosurgery Limited (ASX:ARX) After Its Annual Results

An Intrinsic Calculation For Aroa Biosurgery Limited (ASX:ARX) Suggests It's 27% Undervalued

Mar 22
An Intrinsic Calculation For Aroa Biosurgery Limited (ASX:ARX) Suggests It's 27% Undervalued

Do Institutions Own Aroa Biosurgery Limited (ASX:ARX) Shares?

Feb 24
Do Institutions Own Aroa Biosurgery Limited (ASX:ARX) Shares?

Don't Ignore The Fact That This Insider Just Sold Some Shares In Aroa Biosurgery Limited (ASX:ARX)

Feb 24
Don't Ignore The Fact That This Insider Just Sold Some Shares In Aroa Biosurgery Limited (ASX:ARX)

Aroa Biosurgery Limited's (ASX:ARX) Intrinsic Value Is Potentially 44% Above Its Share Price

Dec 16
Aroa Biosurgery Limited's (ASX:ARX) Intrinsic Value Is Potentially 44% Above Its Share Price

Gelir ve Gider Dağılımı

Aroa Biosurgery nasıl para kazanır ve harcar. LTM bazında en son bildirilen kazançlara dayanmaktadır.


Kazanç ve Gelir Geçmişi

ASX:ARX Gelir, gider ve kazançlar (NZD Millions )
TarihGelirKazançlarG+A GiderleriAr-Ge Giderleri
31 Mar 2469-11629
31 Dec 2367-9599
30 Sep 2366-85610
30 Jun 2365-45210
31 Mar 236304811
31 Dec 2257-14211
30 Sep 2251-23711
30 Jun 2245-53410
31 Mar 2240-8318
31 Dec 2135-10288
30 Sep 2131-11267
30 Jun 2127-15247
31 Mar 2122-19226
31 Dec 2022-19216
30 Sep 2021-19205
30 Jun 2023-12185
31 Mar 2025-6175
31 Mar 19241125
31 Mar 1811-143

Kaliteli Kazançlar: ARX is currently unprofitable.

Büyüyen Kar Marjı: ARX is currently unprofitable.


Serbest Nakit Akışı ve Kazanç Analizi


Geçmiş Kazanç Büyüme Analizi

Kazanç Eğilimi: ARX is unprofitable, but has reduced losses over the past 5 years at a rate of 11.5% per year.

Büyüme Hızlandırma: Unable to compare ARX's earnings growth over the past year to its 5-year average as it is currently unprofitable

Kazançlar vs. Sektör: ARX is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (2.5%).


Özkaynak Getirisi

Yüksek ROE: ARX has a negative Return on Equity (-11.19%), as it is currently unprofitable.


Varlık Getirisi


Kullanılan Sermaye Getirisi


Geçmişte güçlü performans gösteren şirketleri keşfedin